Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDT-3594 in Advanced Parkinson's Disease With Levodopa
NCT06722729Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing KDT-3594 with Placebo (2 arms). Primary endpoint: Change from baseline in the MDS-UPDRS Part II+III (ON-time) total score at 17 weeks. Started Dec 2024; status: completed.
02
Drugs
matsupexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06722729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722729.